|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2009-10-28
|
|
pubmed:abstractText |
Bevacizumab significantly improves survival when added to chemotherapy for metastatic colorectal cancer (mCRC). The Bevacizumab Expanded Access Trial (BEAT) evaluated the safety and efficacy of bevacizumab plus first-line chemotherapy in a general cohort of patients with mCRC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:BerrySS,
pubmed-author:BridgewaterJJ,
pubmed-author:CanonJ-LJL,
pubmed-author:CunninghamDD,
pubmed-author:DiBartolomeoMM,
pubmed-author:First BEAT investigators,
pubmed-author:GeorgouliasVV,
pubmed-author:KretzschmarAA,
pubmed-author:MazierM-AMA,
pubmed-author:MichaelMM,
pubmed-author:PeetersMM,
pubmed-author:RiveraFF,
pubmed-author:Van CutsemEE
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1842-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19406901-Adult,
pubmed-meshheading:19406901-Aged,
pubmed-meshheading:19406901-Aged, 80 and over,
pubmed-meshheading:19406901-Antibodies, Monoclonal,
pubmed-meshheading:19406901-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19406901-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19406901-Camptothecin,
pubmed-meshheading:19406901-Colorectal Neoplasms,
pubmed-meshheading:19406901-Deoxycytidine,
pubmed-meshheading:19406901-Disease-Free Survival,
pubmed-meshheading:19406901-Female,
pubmed-meshheading:19406901-Fluorouracil,
pubmed-meshheading:19406901-Humans,
pubmed-meshheading:19406901-Kaplan-Meier Estimate,
pubmed-meshheading:19406901-Leucovorin,
pubmed-meshheading:19406901-Male,
pubmed-meshheading:19406901-Middle Aged,
pubmed-meshheading:19406901-Organoplatinum Compounds,
pubmed-meshheading:19406901-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
|
|
pubmed:affiliation |
University Hospital Gasthuisberg, Leuven, Belgium. eric.vancutsem@uz.kuleuven.ac.be
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
